Travere Therapeutics, Inc. Overview
Pro stress-test →Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. The company is experiencing exceptional commercial momentum with FILSPARI generating $322 million in 2025, a 144% increase year-over-year.
Strategic Profile
Pro stress-test →FILSPARI (sparsentan) is a once-daily oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy, and the company also markets Thiola and Thiola EC for cystinuria treatment. The company is pursuing FDA approval for FILSPARI in FSGS with a PDUFA target action date of January 13, 2026.
Competitive Landscape
Pro stress-test →Travere competes in the rare kidney disease market alongside other specialized biopharmaceutical companies. The company faces challenges related to product dependence and supply chain management, but has opportunities for growth through pipeline expansion and global market penetration. The company's focus on rare kidney and metabolic diseases provides a differentiated market position.
Industry Context
Travere Therapeutics, Inc. operates in Biopharmaceutical - Rare Kidney and Metabolic Diseases.
Key facts
Founded: 2008 · Headquarters: San Diego, US · Revenue: $410M · Market cap: $1.3B